A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 52 Weeks of Treatment
Launched by TAKEDA · Oct 12, 2023
Trial Information
Current as of May 30, 2025
Active, not recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a new treatment called TAK-279 for people with moderate to severe plaque psoriasis, which is a skin condition that causes red, scaly patches. The main goal of the trial is to see how effectively TAK-279 reduces these skin plaques compared to a placebo (a treatment that does not contain active medication) and another approved treatment called apremilast. Participants will be part of the study for up to 61 weeks and will receive one of the three treatments.
To be eligible for this trial, participants should have had plaque psoriasis for at least six months and have moderate to severe symptoms. They should also be suitable candidates for other treatments like light therapy or systemic therapy, which affects the whole body. However, people with other types of psoriasis, recent infections, or who have previously used TAK-279 or related treatments will not be included. Overall, participants in this trial can expect regular check-ins and evaluations to monitor their skin condition and any side effects from the treatments.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Plaque psoriasis for at least 6 months.
- • 2. Moderate to severe disease.
- • 3. Candidate for phototherapy or systemic therapy.
- Exclusion Criteria:
- • 1. Other forms of psoriasis.
- • 2. History of recent infection.
- • 3. Prior exposure to TAK-279 or active comparator.
- • Other protocol defined inclusion/exclusion criteria apply.
About Takeda
Takeda Pharmaceutical Company Limited is a global, research-driven biopharmaceutical organization committed to advancing patient care through innovative therapies. Founded in 1781 and headquartered in Osaka, Japan, Takeda focuses on key therapeutic areas including oncology, gastroenterology, neuroscience, and rare diseases. With a strong emphasis on research and development, Takeda leverages cutting-edge science and technology to deliver transformative medicines that address unmet medical needs. The company is dedicated to sustainability and ethical practices, ensuring that its clinical trials uphold the highest standards of safety and efficacy while fostering collaboration with healthcare professionals and communities worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Parkville, Victoria, Australia
Shijiazhuang, Hebei, China
Shinjuku Ku, Tokyo, Japan
Tainan, , Taiwan
Chongqing, Chongqing, China
Jinan, Shandong, China
Wuhan, Hubei, China
Beijing, Beijing, China
Shenyang, Liaoning, China
Guangzhou, Guangdong, China
London, Ontario, Canada
Beijing, Beijing, China
Taipei City, , Taiwan
Kaohsiung City, , Taiwan
New Taipei City, , Taiwan
Fuzhou, Fujian, China
Seoul, , Korea, Republic Of
Seoul, , Korea, Republic Of
Yinchuan, Ningxia, China
Hangzhou, Zhejiang, China
Genova, Liguria, Italy
Münster, Nordrhein Westfalen, Germany
Guangzhou, Guangdong, China
Shenzhen, Guangdong, China
Wuhan, Hubei, China
Wonju, , Korea, Republic Of
Shinjuku Ku, Tokyo, Japan
Beijing, Beijing, China
Guangzhou, Guangdong, China
Isehara Shi, Kanagawa, Japan
Krakow, , Poland
Taoyuan City, , Taiwan
Bydgoszcz, , Poland
Warszawa, Mazowieckie, Poland
Xian, Shaanxi, China
Portsmouth, New Hampshire, United States
Warszawa, Mazowieckie, Poland
Lublin, Lubelskie, Poland
San Donato Milanese, Lombardia, Italy
Fountain Valley, California, United States
Jongno Gu, Seoul Teugbyeolsi, Korea, Republic Of
Seoul, Seoul Teugbyeolsi, Korea, Republic Of
Lübeck, Schleswig Holstein, Germany
Henderson, Nevada, United States
Fountain Valley, California, United States
Fremont, California, United States
Hialeah, Florida, United States
Rolling Meadows, Illinois, United States
Indianapolis, Indiana, United States
Troy, Michigan, United States
Warren, Michigan, United States
Bexley, Ohio, United States
Murfreesboro, Tennessee, United States
Portsmouth, New Hampshire, United States
Coral Gables, Florida, United States
Ajax, Ontario, Canada
Barrie, Ontario, Canada
Lódz, Lódzkie, Poland
Bialystok, Podlaskie, Poland
Itabashi Ku, Tokyo, Japan
Phoenix, Arizona, United States
Fort Lauderdale, Florida, United States
Miami, Florida, United States
Ocala, Florida, United States
Marietta, Georgia, United States
Savannah, Georgia, United States
Idaho Falls, Idaho, United States
Charleston, South Carolina, United States
Bellaire, Texas, United States
San Antonio, Texas, United States
Columbia, Maryland, United States
New York, New York, United States
Cary, North Carolina, United States
Surrey, British Columbia, Canada
Etobicoke, Ontario, Canada
Guelph, Ontario, Canada
North Bay, Ontario, Canada
North York, Ontario, Canada
Toronto, Ontario, Canada
Warszawa, Mazowieckie, Poland
East Melbourne, Victoria, Australia
Los Angeles, California, United States
Sacramento, California, United States
Lebanon, New Hampshire, United States
Rozzano, Lombardia, Italy
Kagoshima Shi, Kagosima, Japan
Kumamoto, , Japan
Wroclaw, Dolnoslaskie, Poland
Nadarzyn, Mazowieckie, Poland
Warsaw, Mazowieckie, Poland
Gdansk, Pomorskie, Poland
Gdynia, Pomorskie, Poland
Szczecin, Zachodniopomorskie, Poland
Lodz, , Poland
Blankenfelde Mahlow, Brandenburg, Germany
Gdańsk, Pomorskie, Poland
Poznań, Wielkopolskie, Poland
Idaho Falls, Idaho, United States
Indianapolis, Indiana, United States
Kogarah, New South Wales, Australia
Benowa, Queensland, Australia
Carlton, Victoria, Australia
Parkville, Victoria, Australia
Beijing, Beijing, China
Shanghai, Shanghai, China
Catania, Sicilia, Italy
Firenze, Toscana, Italy
Obihiro Shi, Hokkaidô, Japan
Sapporo Shi, Hokkaidô, Japan
Sapporo Shi, Hokkaidô, Japan
Fukuoka Shi, Hukuoka, Japan
Sumida Ku, Tokyo, Japan
Shimotsuke Shi, Totigi, Japan
Sakai Shi, ôsaka, Japan
Gwangju, Gwangju Gwang'yeogsi, Korea, Republic Of
Bundang Gu, Gyeonggido, Korea, Republic Of
Bundang, Gyeonggido, Korea, Republic Of
Wonju, Ohio, Korea, Republic Of
Gwangjin, Seoul Teugbyeolsi, Korea, Republic Of
Seocho, Seoul Teugbyeolsi, Korea, Republic Of
Warsaw, Mazowieckie, Poland
Warszawa, Mazowieckie, Poland
Warszawa, Mazowieckie, Poland
Katowice, Slaskie, Poland
Zhong Zheng Qu, , Taiwan
Parkville, Victoria, Australia
Calgary, Alberta, Canada
Wenzhou, Zhejiang, China
Oldenburg (Oldenburg), Niedersachsen, Germany
L'aquila, Abruzzo, Italy
Napoli, Campania, Italy
Milano, Lombardia, Italy
Seo Gu, Busan Gwangyeogsi, Korea, Republic Of
Daejeon, Daejeon Gwang'yeogsi, Korea, Republic Of
Savannah, Georgia, Korea, Republic Of
Bucheon Si, Gyeonggido, Korea, Republic Of
Bundang Gu Seongnam Si, Gyeonggido, Korea, Republic Of
Gwangjin Gu, Seoul Teugbyeolsi, Korea, Republic Of
Seocho Gu, Seoul Teugbyeolsi, Korea, Republic Of
Warsaw, Mazowieckie, Poland
Hsinchu, , Taiwan
Brisbane, Queensland, Australia
Nagoya Shi, Aiti, Japan
Seoul, Seoul Teugbyeolsi, Korea, Republic Of
Taipei, , Taiwan
Patients applied
Trial Officials
Study Director
Study Director
Takeda
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported